Total compensation includes information disclosed in company proxy statements, including base salary, bonus, stock awards and option awards, as well as other benefits and perks.
1. Albert Bourla, PhD, Pfizer (New York City) — $30.54 million
2. Christopher Viehbacher, Biogen (Cambridge, Mass.) — $30.49 million
3. Ari Bousbib, IQVIA Holdings (Durham, N.C.) — $29.71 million
4. Marc Casper, Thermo Fisher Scientific (Waltham, Mass.) — $28.21 million
5. Franis deSouza, Illumina (San Diego) — $26.75 million *Mr. deSouza left the CEO position June 11.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
